David H Sachs1, Cesare Galli. 1. Massachusetts General Hospital, Transplantation Biology Research Center, Boston, Massachusetts 02129, USA. david.sachs@tbrc.mgh.harvard.edu
Abstract
PURPOSE OF REVIEW: Recent developments in the field of genetic engineering have made it possible to add, delete or exchange genes from one species to another. This technology has special relevance to the field of xenotransplantation, in which the elimination of a species-specific disparity could make the difference between success and failure of an organ transplant. This review focuses on developments in both the techniques and applications of genetically modified animals. RECENT FINDINGS: Advances have been made using existing techniques for genetic modifications of swine and in the development of new, emerging technologies, including enzymatic engineering and the use of small interfering RNA. Applications of the modified animals have provided evidence that genetically modified swine have the potential to overcome both physiologic and immunologic barriers that have previously impeded this field. The use of alpha-1,3-galactosyltransferase gene-knockout animals as donors have shown marked improvements in xenograft survivals. SUMMARY: Techniques for genetic engineering of swine have been directed toward avoiding naturally existing cellular and antibody responses to species-specific antigens. Organs from genetically engineered animals have enjoyed markedly improved survivals in nonhuman primates, especially in protocols directed toward the induction of tolerance, presumably by avoiding immunization to new antigens.
PURPOSE OF REVIEW: Recent developments in the field of genetic engineering have made it possible to add, delete or exchange genes from one species to another. This technology has special relevance to the field of xenotransplantation, in which the elimination of a species-specific disparity could make the difference between success and failure of an organ transplant. This review focuses on developments in both the techniques and applications of genetically modified animals. RECENT FINDINGS: Advances have been made using existing techniques for genetic modifications of swine and in the development of new, emerging technologies, including enzymatic engineering and the use of small interfering RNA. Applications of the modified animals have provided evidence that genetically modified swine have the potential to overcome both physiologic and immunologic barriers that have previously impeded this field. The use of alpha-1,3-galactosyltransferase gene-knockout animals as donors have shown marked improvements in xenograft survivals. SUMMARY: Techniques for genetic engineering of swine have been directed toward avoiding naturally existing cellular and antibody responses to species-specific antigens. Organs from genetically engineered animals have enjoyed markedly improved survivals in nonhuman primates, especially in protocols directed toward the induction of tolerance, presumably by avoiding immunization to new antigens.
Authors: Angelo Lombardo; Pietro Genovese; Christian M Beausejour; Silvia Colleoni; Ya-Li Lee; Kenneth A Kim; Dale Ando; Fyodor D Urnov; Cesare Galli; Philip D Gregory; Michael C Holmes; Luigi Naldini Journal: Nat Biotechnol Date: 2007-10-28 Impact factor: 54.908
Authors: Jose L Estrada; Bruce Collins; Abby York; Steve Bischoff; Jeff Sommer; Shengdar Tsai; Robert M Petters; Jorge A Piedrahita Journal: Cloning Stem Cells Date: 2008-06
Authors: Akira Shimizu; Yosuke Hisashi; Kenji Kuwaki; Yau-Lin Tseng; Frank J M F Dor; Stuart L Houser; Simon C Robson; Henk-Jan Schuurman; David K C Cooper; David H Sachs; Kazuhiko Yamada; Robert B Colvin Journal: Am J Pathol Date: 2008-05-08 Impact factor: 4.307
Authors: Christopher S Rogers; Yanhong Hao; Tatiana Rokhlina; Melissa Samuel; David A Stoltz; Yuhong Li; Elena Petroff; Daniel W Vermeer; Amanda C Kabel; Ziying Yan; Lee Spate; David Wax; Clifton N Murphy; August Rieke; Kristin Whitworth; Michael L Linville; Scott W Korte; John F Engelhardt; Michael J Welsh; Randall S Prather Journal: J Clin Invest Date: 2008-04 Impact factor: 14.808
Authors: Stefán R Jónsson; Rebecca S LaRue; Mark D Stenglein; Scott C Fahrenkrug; Valgerdur Andrésdóttir; Reuben S Harris Journal: PLoS One Date: 2007-09-12 Impact factor: 3.240
Authors: M Tasaki; I Wamala; A Tena; V Villani; M Sekijima; V Pathiraja; R A Wilkinson; S Pratts; T Cormack; E Clayman; J S Arn; A Shimizu; J A Fishman; D H Sachs; K Yamada Journal: Am J Transplant Date: 2015-02-12 Impact factor: 8.086
Authors: Kazuhiko Yamada; Masayuki Tasaki; Mitsuhiro Sekijima; Robert A Wilkinson; Vincenzo Villani; Shannon G Moran; Taylor A Cormack; Isabel M Hanekamp; Robert J Hawley; J Scott Arn; Jay A Fishman; Akira Shimizu; David H Sachs Journal: Transplantation Date: 2014-08-27 Impact factor: 4.939